Hohl Benjamin sold $232K of ELVN

Enliven Therapeutics plans to initiate a Phase 3 trial of relcobatinib for chronic myeloid leukemia before year-end 2026. The company appointed Kristine Ball to its board, bringing extensive biotech experience. Enliven aims to commercialize relcobatinib, pending trial success and regulatory approval.

Guggenheim reiterated a Buy rating and $78 price target for Enliven Therapeutics (ELVN) after FDA alignment on its Phase 3 study design for relcobatinib. The stock is down 10.5% this week but up 169% YTD. Multiple analysts have initiated coverage with positive ratings and price targets ranging from $70 to $78. The Phase 3 trial will enroll 450 patients and is set to start by year-end 2026.

Enliven Therapeutics (ELVN) and the FDA agreed on a phase 3 trial design for relcobatinib to treat chronic myeloid leukemia in patients who have failed prior treatments. The ENABLE-2 trial will enroll 450 adults.

Enliven Therapeutics (ELVN) reached FDA agreement on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. The ENABLE-2 trial will compare relcobatinib to second-generation TKIs, with a target enrollment of 450 patients. The company plans to initiate the trial by year-end 2026.

Enliven Therapeutics (ELVN) reported FDA alignment on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. This milestone indicates readiness for Phase 3 testing. According to the company, larger catalysts include trial initiation, enrollment progress, and positive results.

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.